2024
Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service Medicare
2016
Prostate Cancer, Version 1.2016.
Mohler J, Armstrong A, Bahnson R, D'Amico A, Davis B, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Kane C, Kawachi M, Kuettel M, Lee R, Meeks J, Penson D, Plimack E, Pow-Sang J, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus T, Small E, Sonpavde G, Srinivas S, Strope S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 1.2016. Journal Of The National Comprehensive Cancer Network 2016, 14: 19-30. PMID: 26733552, DOI: 10.6004/jnccn.2016.0004.Peer-Reviewed Original ResearchConceptsProstate cancerMetastatic castration-recurrent prostate cancerCastration-recurrent prostate cancerTreatment of recurrent diseaseDiagnosis of prostate cancerRisk stratification methodsTreatment of menMetastatic diseaseRecurrent diseaseSystemic therapyNCCN GuidelinesHigh riskDiseaseDisease monitoringCancerNCCNManagement optionsStratification methodTreatmentRiskOptionsProstateTherapyGuidelinesDiagnosis